Xeris Biopharma Holdings Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
XERS Nasdaq 8731 https://www.xerispharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Xeris Biopharma Holdings Inc

Xeris Biopharma to Participate at the Jefferies Healthcare Conference - Jun 1st, 2023 11:00 am
Q1 2023 Xeris Biopharma Holdings Inc Earnings Call - May 10th, 2023 3:33 am
Xeris Biopharma Reports First Quarter 2023 Financial Results - May 9th, 2023 11:00 am
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are individual investors with 56% stake, while 33% is held by institutions - May 8th, 2023 10:37 am
Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023 - May 2nd, 2023 11:00 am
Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ Formulations - Apr 18th, 2023 11:00 am
Subdued Growth No Barrier To Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) With Shares Advancing 61% - Apr 17th, 2023 10:25 am
Strong week for Xeris Biopharma Holdings (NASDAQ:XERS) shareholders doesn't alleviate pain of one-year loss - Apr 6th, 2023 12:21 pm
Xeris Biopharma enters research collaboration with Regeneron Pharmaceuticals to advance XeriJect - Apr 5th, 2023 5:18 pm
Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect™ - Mar 30th, 2023 11:00 am
Xeris Biopharma Appoints Ricki Fairley to Board of Directors - Mar 29th, 2023 8:05 pm
Q4 2022 Xeris Biopharma Holdings Inc Earnings Call - Mar 9th, 2023 4:52 am
Xeris Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance - Mar 8th, 2023 11:00 am
Xeris Biopharma to Report Fourth Quarter and Full-Year 2022 Financial Results on March 8, 2023 - Feb 23rd, 2023 12:00 pm
Xeris Biopharma to Participate in the SVB Securities Global Biopharma Conference 2023 - Feb 2nd, 2023 12:00 pm
Xeris Biopharma Announces FDA Grants Orphan-drug Exclusivity for Recorlev® - Jan 30th, 2023 12:00 pm
Xeris Biopharma to Present at 41st Annual J.P. Morgan Healthcare Conference - Jan 5th, 2023 9:03 pm
Xeris Biopharma Updates Its Outlook For 2022 - Jan 5th, 2023 12:00 pm
A Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider increased their holdings by 16% last year - Dec 31st, 2022 2:33 pm
Xeris Biopharma Announces Plans for a Phase II Dose-Finding Study for Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) as Replacement Therapy for Hypothyroidism - Dec 15th, 2022 12:00 pm